DB
FULC icon

Dmitry Balyasny’s Fulcrum Therapeutics FULC Stock Holding History

Dmitry Balyasny’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
692,372
-1,087,574
-61% -$6.62M ﹤0.01% 1699
2026
Q1 		$13.7M Buy
1,779,946
+809,507
+83% +$7.51M 0.02% 870
2025
Q4 		$11M Sell
970,439
-480,041
-33% -$4.89M 0.01% 976
2025
Q3 		$13.3M Buy
1,450,480
+112,266
+8% +$812K 0.02% 911
2025
Q2 		$9.21M Buy
+1,338,214
New +$7.16M 0.01% 1006
2024
Q4 		– Sell
-10,374
Closed -$37K – 2917
2024
Q3 		$37K Sell
10,374
-993
-9% -$7.37K ﹤0.01% 2651
2024
Q2 		$70.5K Sell
11,367
-4,342
-28% -$32.9K ﹤0.01% 2425
2024
Q1 		$148K Sell
15,709
-89,470
-85% -$799K ﹤0.01% 2459
2023
Q4 		$710K Buy
+105,179
New +$467K ﹤0.01% 1818
2023
Q3 		– Sell
-11,087
Closed -$36.6K – 2414
2023
Q2 		$36.6K Buy
+11,087
New +$32.6K ﹤0.01% 2142
2022
Q3 		– Sell
-15,684
Closed -$77K – 2975
2022
Q2 		$77K Buy
+15,684
New +$153K ﹤0.01% 2310
2022
Q1 		– Sell
-11,734
Closed -$208K – 2595
2021
Q4 		$208K Buy
+11,734
New +$232K ﹤0.01% 1838

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's FULC Position: Q2 2026 in Review

Dmitry Balyasny reduced its Fulcrum Therapeutics (FULC) stake by 61% in Q2 2026, selling an estimated $6.62M and leaving 692,372 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

Dmitry Balyasny first reported a position in FULC in Q4 2021 and has held it in 12 quarters since. The position peaked at $13.7M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Dmitry Balyasny held 692,372 shares of Fulcrum Therapeutics worth $2.53M as of Q2 2026.
  • Dmitry Balyasny sold 1,087,574 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.62M.
  • Fulcrum Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1699 holding.
  • Dmitry Balyasny first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Dmitry Balyasny's Fulcrum Therapeutics position peaked at $13.7M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.